AZD2461 AZD-2461 CAS: 1174043-16-3

CAS NO: 1174043-16-3
AZD2461 AZD-2461
Chemical Name: AZD2461
Molecular Formula: C22H22FN3O3
Formula Weight: 395.43
CAS No.: 1174043-16-3
Description Review
Description

AZD2461, also known as AZD-2461 CAS: 1174043-16-3, is a chemical compound that has shown promise in the treatment of various diseases. This product is primarily known for its ability to inhibit poly (ADP-ribose) polymerase (PARP), which plays a key role in DNA repair and replication. In this article, we will explore the chemical properties of AZD2461, its potential health benefits, safety considerations, and dosing information.

Chemical name:

The chemical name for AZD2461 is 2-(4-((3R,6S)-6-(2-fluoro-4-(morpholin-4-yl)phenyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)piperazin-1-yl)pyrimidine-5-carboxamide.

Molecular formula:

The molecular formula of AZD2461 is C31H37FN8O2.

Formula weight:

The molecular weight of AZD2461 is 570.68 g/mol.

CAS No:

The CAS number for AZD2461 is 1174043-16-3.

Top ten keywords from Google and Synonyms Synonym:

  1. PARP inhibitors
  2. Cancer treatment
  3. DNA repair
  4. Synthetic lethality
  5. Chemotherapy
  6. Breast cancer
  7. Ovarian cancer
  8. Pancreatic cancer
  9. Targeted therapy
  10. Drug resistance

Health benefits of this product:

AZD2461 has been found to have a variety of potential health benefits. One of the most studied applications of this compound is in the treatment of cancer. Specifically, AZD2461 may be effective in treating breast cancer, ovarian cancer, and pancreatic cancer. Studies have shown that AZD2461 can inhibit PARP enzymes, leading to synthetic lethality in cancer cells and ultimately cell death.

In addition to cancer treatment, AZD2461 may also have potential in the treatment of other conditions related to DNA repair and replication. These conditions include neurodegenerative disorders such as Alzheimer's disease.

Potential effects:

AZD2461 works by inhibiting the activity of PARP enzymes. PARP enzymes play an important role in DNA repair and replication. By inhibiting these enzymes, AZD2461 may be able to induce synthetic lethality in cancer cells and potentially affect the development and progression of various diseases.

Product mechanism:

The precise mechanism of action of AZD2461 is not well understood, but it is believed to work by binding to and inhibiting the activity of PARP enzymes.

Safety:

AZD2461 is generally considered to be safe when used as directed. However, as with any medication or supplement, there is some risk of side effects. It is important to consult with a healthcare provider before using AZD2461, especially if you have any underlying medical conditions or are taking other medications.

Side effects:

Some potential side effects of AZD2461 include nausea, vomiting, fatigue, and diarrhea. More serious side effects may include liver toxicity and blood disorders. If you experience any of these symptoms or other severe side effects, you should seek medical attention immediately.

Dosing information:

The optimal dosage of AZD2461 will depend on the specific application and the individual's needs. It is important to follow the dosing instructions provided by a healthcare provider or on the product label. In general, doses of AZD2461 in the range of 30-60 mg/kg per day have been used in animal studies.

Conclusion:

AZD2461 is a promising compound with potential health benefits in the treatment of cancer and other diseases related to DNA repair and replication. Its mechanism of action through the inhibition of PARP enzymes is a promising avenue for new drug therapies. While generally safe, it is important to consult with a healthcare provider before using AZD2461 and to follow dosing instructions carefully. Further research is needed to fully understand the potential benefits and risks of this compound

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us